Proteins by Design®

XmAb® Antibody Therapeutics

Corporate Overview

October 2024

Forward-Looking Statements

Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trials; the plans and objectives of management for future operations; and the potential markets for Xencor's product and development candidates. Forward-looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and involve numerous risks and uncertainties, many of which are beyond Xencor's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, but are not limited to, potential delays in development timelines or negative preclinical or clinical trial results, reliance on third parties for development efforts and changes in the competitive landscape including changes in the standard of care, as well as other risks described in Xencor's filings with the Securities and Exchange Commission (SEC). Xencor expressly disclaims any duty, obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in Xencor's expectations with regard thereto of any subsequent change in events, conditions or circumstances on which any such statements are based, except in accordance with applicable securities laws. For all forward-looking statements, we claim the protection of the safe harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995.

Proven Power of XmAb® Engineering: Proteins By Design®

Small changes, big functional impacts

- XmAb Fc Domains augment native immune functions in molecules and/or control their structure, while preserving desired attributes
- XmAb engineered antibodies are designed to solve complex biologic problems
- Strong patent portfolio with over 1,600 patents issued and pending worldwide



Advancing an optimized portfolio of XmAb drug candidates

- **Oncology:** 3 novel TCEs advancing in Phase 1 studies; narrow focus for vudalimab in mCRPC and 1L NSCLC
- **Autoimmune**: Upcoming study initiation plans
  - 4Q'24: XmAb942 (Xtend™ TL1A)
  - 1H'25: Plamotamab (CD20xCD3) in RA
  - 2H'25: XmAb657 (CD19xCD3)



XmAb Bispecific T-cell Engagers (TCEs)

Xtend™ Antibodies with Potential Best-in-class Half-life Extension

Partnerships leverage modular XmAb technology

- More than 15 technology license partnerships greatly broadens scope with little-to-no effort
- Multiple commercialized XmAb antibodies

ULTOMIRIS® **MONJUVI®/MINJUVI®**

COLLABORATION PORTFOLIO INCLUDES

Johnson&Johnson Innovative Medicine · AMGEN · ALEXION AstraZeneca Rare Disease · Incyte · Genentech A Member of the Roche Group · GILEAD · VIR · astellas

Registered trademarks: Ultomiris® (Alexion Pharmaceuticals, Inc.), Monjuvi® & Minjuvi® (Incyte Holdings Corp.)

xencor

Xencor's Disciplined Drug Development Strategy



* As of 6/30/2024. Includes cash, cash equivalents & marketable debt. Updated 8/5/2024.

Next-Gen XmAb® Drug Design in Oncology & Autoimmune Diseases

Pipeline focus on T-cell engagers and bispecific mechanisms

Program	Targets	XmAb® Platforms	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Solid Tumor Oncology: T-cell Engagers (CD3 & CD28)								
XmAb819	ENPP3 x CD3	2+1 Bispecific	ccRCC					
XmAb808	B7-H3 x CD28	2+1 Bispecific, Xtend™	Prostate cancer, oncology			+ pembrolizumab		
XmAb541	CLDN6 x CD3	2+1 Bispecific, Xtend	Ovarian cancer, oncology					
XmAb Program	Undisclosed TCE	Bispecific, Xtend	Solid tumor oncology					
Solid Tumor Oncology: T-cell Selective, Dual Checkpoint Inhibitor								
Vudalimab	PD-1 x CTLA-4	Bispecific, Xtend	mCRPC			+/- chemotherapy		
			1L NSCLC			+ chemotherapy		
Immunology Programs								
Plamotamab	CD20 x CD3	Bispecific	Rheumatoid Arthritis				1H'25	
XmAb942	TL1A	Xtend, FcKO	Inflammatory Bowel Diseases (IBD)				4Q'24	
XmAb657	CD19 x CD3	2+1 Bispecific, Xtend	Autoimmune Diseases				2H'25	
XmAb Program	TL1A x IL23	Bispecific, Xtend	Autoimmune Diseases					

ccRCC clear cell renal cell carcinoma **NSCLC** non-small cell lung cancer
mCRPC metastatic castration-resistant prostate cancer **FcKO** Fc knock out

Key: Solid tumors | Immunology | Planned Study Initiation

xencor

XmAb® Technologies Create Numerous Differentiated Antibodies for Technology Partners

Technology licensing expands pipeline with very little opportunity cost

Selected Programs	Fc Domain	Indications	Preclinical	Phase 1	Phase 2	Phase 3	Marketed	Commercial Rights
Ultomiris®	Xtend™	PNH, aHUS, gMG, NMOSD						Alexion, AstraZeneca Rare Disease
Monjuvi®	Cytotoxic	DLBCL						Incyte
Xevudy®	Xtend	COVID-19				NOT CURRENTLY AUTHORIZED IN U.S.		VIR
Obexelimab	Immune Inhibitor	IgG4-RD, wAIHA						Zenas BioPharma
Tobevibart (VIR-3434)	Cytotoxic Xtend	Hepatitis B Hepatitis D						VIR
Xaluritamig STEAP1 x **CD3**	2+1 Bispecific	Prostate cancer						Amgen
Efbalropendekin alfa IL15/IL15Rα-Fc	Bispecific Xtend	r/r multiple myeloma		+ daratumumab + cevostamab				Genentech, A Member of the Roche Group
		Oncology		+ atezolizumab				
ASP2138 CLDN18.2 x **CD3**	2+1 Bispecific	Oncology						Astellas
JNJ-9401 PSMA x **CD28**	Bispecific	Prostate cancer						Johnson&Johnson Innovative Medicine
JNJ-1493 CD20 x **CD28**	Bispecific	Heme-Onc						Johnson&Johnson Innovative Medicine

Key XmAb Bispecific | XmAb Tech (Non-BsAb)

Registered trademarks: Ultomiris® (Alexion Pharmaceuticals, Inc.), Monjuvi® (Incyte Holdings Corp.) Xevudy® (Glaxo Group Limited)

xencor

XmAb® Bispecific T Cell Engagers

*XmAb **2+1** Bispecific Antibody Format*

XmAb819 (ENPP3 x CD3)

XmAb541 (CLDN6 x CD3)

XmAb808 (B7-H3 x CD28)

XmAb® T Cell Engagers Use Multiple Formats and Affinity Designs to Customize for Each Tumor Target

XmAb® 1+1

Targets: tumor antigen (e.g., CD20, CD38)

1 Fab

1 scFv
Targets: CD3 or CD28



Example
Plamotamab CD3

XmAb® 2+1

Targets: tumor antigen (e.g., ENPP3, STEAP1, Claudin 18.2, B7-H3)

2 Fabs

1 ScFv
Targets: CD3 or CD28



Examples

Xaluritamig	CD3
ASP2138	CD3
XmAb819	CD3
XmAb541	CD3
XmAb808	CD28

Tuned 2+1 Format = Selective Reactivity



CD3 affinity tuned for reduction of cytokine release syndrome and off-tumor cell killing

Tumor antigen binding affinity tuned for tumor expression density and to match format

xencor

XmAb®819: CD3 T-cell Engager for Renal Cell Carcinoma in Phase 1

Encouraging Initial Data in Ongoing Dose Escalation in ccRCC

XmAb 2+1 Design



XmAb819 (ENPP3 x CD3)

ENPP3: high RCC; low healthy tissues



Selective T cell directed cytotoxicity



Phase 1 Dose Escalation Study

- Dose escalation ongoing in relapsed/refractory clear cell RCC (ccRCC - nearly uniformly high ENPP3 expression
- Administration: IV and subcutaneous cohorts dosing weekly, with priming and step-up doses
- Following determination of RP2D, expansion cohorts planned in ccRCC and other histologies with high ENPP3 expression
- Companion diagnostic under development for potential patient selection in other histologies

Observed in escalation (update 09-Sep-2024)

- Clear initial evidence of anti-tumor activity, including RECIST responses, in recent cohorts
- Duration of treatment for several patients in earlier dose cohorts has extended beyond one year
- Cytokine release syndrome (CRS) manageable
- No MTD reached; tolerability from recent dose cohorts continues to support dose escalation
- Investigators remain highly engaged, and enrollment into new dose cohorts has been rapid
- Intravenous and subcutaneous cohorts continue dose escalation in parallel
- Evaluation of expansion into additional tumor types is ongoing
- **Clinical update and first dose expansion cohort expected to start during 1H'25**

NCT05433142

xencor

XmAb®541: CD3 T-cell Engager for Ovarian Cancer & Solid Tumors

XmAb 2+1 Design



XmAb541 (CLDN6 x CD3)

CLDN6 selective over CLDN9



- Differential expression in cancerous tissue presents CLDN6 as an intriguing target
- CLDN family members, which are small membrane proteins, have high sequence identity, complicating antibody design
- XmAb541 engineered for CLDN6 selectivity over similar CLDN9, CLDN3 and CLDN4
- **Ongoing Phase 1 study; first patient dosed 1H24**

NCT05433142

CLDN6 Avoids Normal Tissue

FDA999w normal tissue staining



CD28 Bispecific Antibodies Provide a Boost to T Cell Activation

CD28 provides "Signal 2" activation



XmAb® CD28 T cell engagers feature low affinity, monovalent binding

- Avoid historic CD28 safety concerns (superagonism)
- Well behaved: stable, silent FcγR interactions, with Xtend™ Fc technology
- Potential to combine with anti-PD1 and/or CD3 T cell engagers

Multiple wholly owned early-stage and actively advancing programs

- Ongoing Phase 1 study of XmAb808 (B7-H3 x CD28) in combination with pembrolizumab in solid tumors
- Presented preclinical data from multiple research-stage programs targeting CEACAM5, STEAP1, ENPP3, Trop2 and MSLN

Two narrow, target-limited collaborations with J&J for CD28 bispecifics

- JNJ-9401 (PSMA x CD28; Phase 1) for combination with J&J CD3 bispecifics; collaboration includes access to J&J prostate-cancer franchise for clinical combinations across Xencor's portfolio
- JNJ-1493 (CD20 x CD28; Phase 1) for J&J's use in combination with agents, such as CD3 bispecifics

XmAb808: Tumor-specific CD28 T-cell Engager Targeted to Broadly Expressed Tumor Antigen B7-H3 in Phase 1

XmAb 2+1 Design



XmAb CD28 T Cell Engagers

Designed to enhance selective T cell activation through CD28 (Signal 2) when in the presence of tumor cells

- Feature low affinity, monovalent binding to CD28
- Avoid CD28 safety concerns (superagonism)
- Well behaved: stable, silent FcγR interactions, with Xtend™ Fc technology
- Potential to combine with anti-PD1 and/or CD3 T cell engagers (Signal 1)

B7-H3 is Broadly Expressed in Solid Tumors

High expression in prostate cancer and others (kidney, breast, lung, etc.)



B7-H3 RNA expression (TCGA)

Clinical Programs

XmAb808: Phase 1 dose-escalation in solid tumors

- Combination with anti-PD1 (Signal 1); pembrolizumab added on third dose, included in all dose escalation cohorts
- Enrolling patients with prostate cancer, ovarian cancer, HNSCC, urothelial cancer and others

Continued progress in escalation (update 09-Sep-2024)

- Tolerability from recent dose cohorts remains supportive of continued combination with per label dosing of pembrolizumab
- Safety data have supported adding cohorts with Day 1 start for dosing the combination of XmAb808 and pembrolizumab, along with cohorts that use a four-week XmAb808 monotherapy run-in period
- Dose-escalation cohorts continue to enroll patients with multiple tumor types, majority with mCRPC
- For the subgroup of mCRPC patients, biologic activity of XmAb808 has been observed with PSA declines during the four-week monotherapy run-in period, but higher doses are expected to be needed to trigger more meaningful clinical activity
- **Clinical update and dose expansion expected to start during 1H'25**

NCT05585034

xencor

New Pipeline Programs:
B-cell Depleting T-cell Engagers

Plamotamab (CD20 x CD3)

XmAb657 (CD19 x CD3)

Plamotamab
Phase 2 Ready, Subcutaneous CD20 x CD3 BsAb

Planned proof-of-concept for the T-cell engager class in autoimmune and inflammatory disease

XmAb® CD20 x CD3 Bispecific Design



- Plamotamab designed in a 1+1 format and selected for extended activity and favorable tolerability observed in NHPs
- Human half-life ~18 days; estimated 80% SC bioavailability
- Robust manufacturing process with high yield and excellent formulation stability data

Positioned for Success

- N=154 from dose escalation and expansion cohorts with both IV and SC formulations in B-cell cancers
- Comparable preliminary efficacy data to leading commercial CD20 x CD3 in patients with prior CAR-T
- IV & SC dosing regimens with improved CRS data vs. leading commercial CD20 x CD3[1]
- Existing inventories of drug product and drug substance for seamless integration into the next phase of clinical development

BsAb bispecific antibody **IV** intravenous, **SC** subcutaneous **NHP** non-human primate **CRS** cytokine release syndrome **1** No head-to-head trial has been conducted evaluating plamotamab against other data included herein. Differences exist between clinical trial design, patient populations and the product candidates themselves, and caution should be exercised when comparing data across trials.

xencor

Single Dose of Plamotamab in NHPs
Durable B-cell Depletion Observed in Blood and Lymphoid Organs

Blood B cells



Bone marrow B cells



Lymph node B cells



xencor

>95-99% Peripheral B-cell Depletion Observed in Lymphoma Patients with IV & SC Plamotamab in Phase 1 Monotherapy Study

- Patients were identified (N=5) that had baseline absolute B-cell count > 30 cells/µL in the blood
- >90% reductions in B-cell count also observed at lower doses



Plamotamab: Plan for Phase 1b/2a Rheumatoid Arthritis Study Start

Maximal efficiency to clinical proof of concept in multi-drug resistant rheumatoid arthritis (MDR-RA)

Phase 1b/2a Study Initiation Planned for 1H'25

Single 1b/2a study for seamless transition to randomized proof-of-concept trial



- Quickly refine priming/step-up dosing regimens used in lymphoma studies
- Assess SC and IV routes, and pre-medication regimen including corticosteroids, to be run in parallel on a staggered start
- Assess safety, biomarkers, initial efficacy in RA patients

- Advance selected dosing regimen into placebo-controlled trial in MDR-RA patients
- Single-cycle dosing in line with other B-cell depleting agents
- 24-week efficacy endpoint with interim efficacy analysis at week 12 with paired biomarker assessment

xencor

XmAb657
CD19 x CD3 Optimized for Autoimmune Disease

Rational XmAb® Design



- High affinity and stability anti-CD19 binder
  - Bivalent to efficiently target B cells expressing very low levels of CD19 (e.g., plasma cells and plasmablasts)
- Affinity-tuned and highly stable anti-CD3 binder
- Uses Xencor's clinically validated 2+1 format
- Heterodimeric Fc domain engineered to abrogate effector function and improve half-life
- Xtend™ Fc for long half life

Positioned for Success

Ongoing NHP studies have shown effective B-cell depletion with single dose

- Broad opportunity set of disease indications supports multiple development pathways for success
- EULAR 2024 and subsequent updates of CD19 CAR-T clinical data highlighted potential issues with CAR-T approach on efficacy and safety
- Rational design of XmAb657 supports best-in-class potential for clinical outcomes
- **Current timeline to FIH study in 2H'25 puts Xencor on-track to be a leading CD19 x CD3 program within autoimmune disease**

Single Dose of XmAb657 in NHPs
Deep B-cell Depletion Sustained for at Least 28 Days

	Peripheral blood	Bone marrow	Lymph nodes
XmAb 657 Single IV Dose (low)			
XmAb657 Single IV Dose (high)			

*peripheral B cells <1 B cell per µL;
‡this data point is zero B cells per µL

B cells were gated as CD45+CD2-/lowCD20+CD4-CD8a-CD159a-

xencor

XmAb657: Rationally Designed for Autoimmune Disease FIH Planned 2H'25

- Has been observed to demonstrate deep and durable B-cell depletion in NHPs, enabled by potentially best-in-class pharmacokinetics
- Has been well tolerated in NHP with no clinical signs of CRS
- GMP production campaign initiated
- Further plans to investigate subcutaneous dosing and priming
- **First-in-human study planned to initiate in 2H'25**



Long half life with Xtend™ Fc technology (~15 days in NHP) has potential for durable B-cell depletion





New Pipeline Programs: TL1A Portfolio

XmAb942 (Xtend™ TL1A)

XmAb TL1A x IL-23

Inflammatory Bowel Disease (IBD) is a Devastating Disease with Significant Unmet Medical Need

~3m
Estimated diagnoses in the US[1]

Two common forms:
Crohn's disease
Ulcerative colitis

Economic burden estimated at $5.4B in 2023[2]

Significant Health Burden

- Impaired quality of life
- Lower life expectancy
- Surgeries, hospitalization
- Increased risk for intestinal resection
- Increased risk for colorectal cancer

Severe Symptoms of IBD

- Fatigue
- Fever
- Reduced appetite
- Mental health

Current Standards of Care are Lacking



Patients cycle through suboptimal treatments

- **Suboptimal efficacy:** ~10-20% disease remission[3]
- **Adverse events:** Infection, malignancy, thromboembolism, cardiac
- **Burdensome regimens:** poor patient compliance

1 Clarivate **2** GlobalData **3** Prescient whitepaper

xencor

Development of XmAb942 and XmAb TL1A x IL-23 for IBD

XmAb942 Design



Xtend™ + FcKO

XmAb TL1A x IL-23 Design



Bispecific
Fc Domain

Phase 2 TL1A Studies and VEGA Study Support Strategy

- Building upon proof-of-concept studies with TL1A targeted therapy and combination therapies for the treatment of Ulcerative Colitis (UC) and Crohn's Disease (CD)
  - Validated best-in-class Xtend™ half-life extension in XmAb942
  - First-in-class potential of TL1A x IL-23 to target dual pathway inhibition

RG6631 Phase 2 TUSCANY (Roche TL1A)
(cross UC study comparison of Endoscopic Improvement)[1]



VEGA Ph2a
(Clinical Remission of UC at Week 38)[2]



1 Sourced from Roivant presentation of TUSCANY, Entyvio (anti-integrin) and Humira (anti-TNF) data from VARSITY P3 study, S1P receptor modulator data from ELEVATE 52 P3 study
2 Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA); Feagan and Shao et al.; The Lancet G&H; Feb 2023

Xtend™ Fc: Validated Half-Life Extension (HLE) Technology Enabling Potential Best-in-Class Anti-TL1A

Clinically validated with significantly improved half-life and dose frequency

- Ultomiris half-life extended >4x as compared to Soliris; maintenance dose frequency reduced by 4X[1]
- VRC01LS half-life extended >4X as compared to parental (71 days vs 15 days)[2]

Similar safety and immunogenicity risk as parental antibodies in studied antibodies using Xtend Fc domains[3,4,5]

Antibody thermostability maintained in studied antibodies using Xtend Fc domains[6,7]

Superior or comparable to other HLE technologies (e.g., YTE) across multiple studies and parameters[6,7,8]

Typical HLE scaling from cyno to human is ~3.5x[9]

Clinical Half-Life and Maintenance Dosing Ultomiris vs. Soliris[10]

Product	Half-life (days)[11]	Dosing Interval[1,12]
Ultomiris (with Xtend™)	**49.7-64.3**	**Q8W**
Soliris	11.33-12.1	Q2W

Proprietary Xtend™ Fc Domain has been incorporated into ≥ 35 molecules that have been tested in clinical studies

Xtend is commonly referred to as 'LS' in academic literature

1 Ultomiris & Soliris drug labels **2** Ledgerwood Clin Exp Imm 2015 **3** Lee et al. Blood 2019 **4** Gaudinski et al. PLOS Med 2018 **5** Vu et al. J Neurol 2023 **6** Ko et al. Exp Mol Med 2022 **7** Internal Data **8** Ko et al. Nature Letter 2014 **9** Haraya & Tachibana. BioDrugs (2023) 37:99–108 **10** Data adapted from FDA and EMA drug labels **11** Reported Half-life across approved indications **12** Maintenance dosing interval in adults

xencor

XmAb942: Novel High-Affinity Anti-TL1A mAb Designed for Extended Half-Life, Under Development for the Treatment of IBD

- XmAb942 utilizes Xtend™ Fc domain technology with potentially class-leading potency
- Half-life in non-human primate studies, 23 days, supports Q8W to Q12W dosing in humans
- High concentration formulation for subcutaneous dosing
- Preclinical discovery and characterization presented during UEG Week 2024
- **First-in-human clinical studies to begin 4Q'24**

Company	Program[1]	Potent	SC Dosing	Q8-12W Dosing	Half-life extension	Low Immunogenicity
Xencor	XmAb942	✓	✓	✓	✓	✓ Predicted
Merck (Prometheus)[2,3]	MK-7240	✗	✓	✗	✗	✓
Roche (Roivant)[4,5]	RG-6631	✓	✓	✗	✗	✗
Sanofi (Teva)[6]	TEV-48574	✓	✓	✗	✗	TBD

1 No head-to-head trial has been conducted evaluating XmAb942 against other data included herein. Differences exist between clinical trial design, patient populations and the product candidates themselves, and caution should be exercised when comparing data across trials **2** PRA023 Progress Update (Prometheus presentation) **3** Feagan et al. The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results (DOP87) Abstract citation ID: jjac190.0127 **4** Banfield et al. Br J Clin Pharmacol. 2020;86:812–824 **5** Clarke et al. mAbs. 2018;10:4, 664-677 **6** Danese et al. Clin Gastroenterology and Hepatology. 2021;19:11, 2324-32.e6

XmAb® TL1A x IL-23 to Have First-in-Class Potential First-in-Human Study Planned in 2026

Prototype TL1A x IL-23p19 bispecifics are functionally active on both axes



XmAb protein engineering allows for a range of stable molecular structures



- Rapidly prototype in multiple formats
- Optimize and tune for biological activity

T Cell Selective,
Dual Checkpoint Inhibitor

Vudalimab (PD-1 x CTLA-4)

Vudalimab: Selective PD-1 x CTLA-4 Bispecific Antibody

- Monotherapy generally well tolerated, with a potentially differentiated profile from two-antibody combination therapy (PD-1 + CTLA-4)
- Xencor's initial focus on tumors with poor PD-1 inhibitor activity: e.g., prostate cancer



Vudalimab is Designed to Promote Tumor-Selective T Cell Targeting



Evolution of Vudalimab Development Program for mCRPC



mCRPC Cohort in Study XmAb717-05

- Visceral, soft tissue, or lymph node metastases (“high-risk” mCRPC)
- Measurable disease by RECIST 1.1
- Progressed after all approved, medically appropriate therapies
- < 2 prior chemotherapy regimens
- No prior treatment with anti-CTLA-4 or PD-1

Study status (February 7, 2024)

- 14/30 mCRPC patients enrolled

Vudalimab Q3W flat dose schedule: 1000 (< 80 kg) or 1200 mg (≥ 80 kg) IV

Preliminary Data for Vudalimab Monotherapy in mCRPC

Vudalimab monotherapy has been associated with clinical response in 5 out of 12 evaluable mCRPC patients with visceral or lymph node metastases

- Findings consistent with observations of durable responses (41 and 27 weeks) in Phase 1 mCRPC cohort in 2 patients with visceral and lymph node (extrapelvic and/or intrapelvic) metastases

Vudalimab monotherapy safety profile has been consistent with other checkpoint inhibitor therapies

- Low rate of discontinuation of treatment due to adverse events

Additional data will inform future development efforts in monotherapy, and/or contribution of monotherapy to combination treatment

NCT05032040 Data cut February 7, 2024.

xencor

Phase 1b/2 Study in 1L NSCLC in combination with chemotherapy

Part 1 dose comparison, Part 2 randomized vs. pembro; ***First patient dosed in Q4 2023***



Encouraging proof-of-concept data in NSCLC supports evaluation of vudalimab in 1L

- Study of volrustomig (PD-1 x CTLA-4) in checkpoint-naïve NSCLC shows superior PFS over pembrolizumab
  - Volrustomig + chemo vs. pembrolizumab + chemo
- Vudalimab Phase 1 Cohort C (20 patients with NSCLC) activity in 3-4L patients
  - Heavily-pretreated population: 95% checkpoint experienced, 40% ≥ 2 prior checkpoints, median 3 prior therapies
  - 14% objective response rate (2 partial responses of 14 evaluable); 50% disease control rate (7/14)

NCT06173505

Guidance for Progress Across XmAb® Portfolio Programs in 2024

XmAb Drug Candidate		2024 Priority
Solid Tumors: T-Cell Engagers (CD3 & CD28)		
XmAb819	ENPP3 x CD3	Advance dose escalation toward target dose levels in 2024
XmAb808	B7-H3 x CD28	Advance dose escalation toward target dose levels in 2024
XmAb541	CLDN6 x CD3	Dose first patient during 1H 2024, enroll Phase 1 study ✓
Immunology		
XmAb942	Xtend™ TL1A	Present preclinical data during UEG Week 2024 ✓
		Initiate first-in-human Phase 1 study in Q4 2024
Plamotamab	CD20 x CD3	Define clinical development plan ✓
XmAb657	CD19 x CD3	GMP campaign and IND preparation ✓

xencor

Potential Inflection Points for Xencor's Clinical Portfolio in 2025

XmAb Drug Candidate		Indication	1H'25	2H'25
Oncology Portfolio				
XmAb819	ENPP3 x CD3	ccRCC	**Initiation of dose expansion**	
XmAb808	B7-H3 x CD28	Solid tumor	**Initiation of dose expansion**	
XmAb541	CLDN6 x CD3	Ovarian+		**Advance toward target dose levels**
Vudalimab	PD-1 x CTLA-4	mCRPC	**Mono & combo cohort expansion readout**	
		NSCLC	**Evaluate chemo combination safety**	
Immunology Portfolio				
XmAb942	Xtend™ TL1A	IBD+	**SAD readout**	**MAD readout and Phase 2 start**
Plamotamab	CD20 x CD3	Rheumatoid arthritis	**Initiate Phase 1/2 study**	
XmAb657	CD19 x CD3	Autoimmune		**Initiate FIH study**

As presented 09-Sep-2024 **SAD** Single ascending dose **MAD** multiple ascending dose **FIH** first-in-human

xencor

Proteins by Design®

XmAb® Antibody Therapeutics

Corporate Overview

October 2024